About Medicinal Glow

Medicinal Glow is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 GHK-Cu blend and its three constituent peptides — GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (Body Protection Compound 157), and TB-500 (the Ac-LKKTETQ synthetic fragment of thymosin beta-4). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "medicinal" in our name refers to our editorial position relative to the literature — a research digest focused on mechanisms, findings, and honest gaps — not a claim about the site's services. No clinical service of any kind is offered here.

We follow the research. BPC-157, TB-500, and GHK-Cu each have independent preclinical evidence bases — BPC-157 with more than thirty rodent studies across tendon, gut, and burn wound models; thymosin beta-4/TB-500 with a record that has advanced to Phase 3 corneal and dermal clinical trials;^[9][19] GHK-Cu with a five-decade literature on collagen synthesis, gene modulation, and wound healing.^[14][15][16] We summarize what these studies measured, in the species they studied it, at the doses they used.

We do not extrapolate rodent dose data to human prescriptions. We do not recommend that anyone take any compound. We are explicit that no study has examined all three components of the BPC-157 TB-500 GHK-Cu blend in co-administration, and that every synergy claim on this site is mechanistic rationale, not empirical co-administration data. Where the evidence is thin — no human clinical trial for the blend, no injectable human PK data for GHK-Cu, no controlled human study for TB-500's synthetic fragment — we say so directly.

Peptides are short amino acid chains — sequences shorter than full proteins — that act as signaling molecules in the body. GHK, the core of GHK-Cu, is naturally present in human plasma and communicates with fibroblasts to upregulate collagen and elastin gene expression at picomolar concentrations.^[16] BPC-157, derived from a gastric protein, activates VEGFR2 receptors on vascular endothelial cells, driving new blood vessel formation in injured tissue.^[1][2] TB-500, the synthetic fragment of the endogenous thymosin beta-4 molecule, binds monomeric actin to control cell migration — the cellular movement mechanism that populates and closes wounds.^[9][19]

Each peptide is a short, specific signaling sequence acting on a defined molecular target. The appeal of the three-component blend as a research framework is that each peptide's target is a different rate-limiting step in tissue repair.

None of the three components of the BPC-157 TB-500 GHK-Cu blend is approved by the FDA or any comparable regulatory body for human therapeutic injection. BPC-157 was placed on the FDA's bulk drug substances list for compounding restrictions in 2023. TB-500 and its parent thymosin beta-4 are prohibited at all times under WADA Prohibited List S2 for competitive athletes. GHK-Cu is not currently on the WADA Prohibited List. These compounds are studied in research settings and discussed here as the subjects of that research — not as treatments, cures, or products available for human use.